NCT00858156View on ClinicalTrials.gov

BG9928 in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Hepatic Impairment

Interventions

DRUG

BG9928

Oral 75 mg single dose

Trial Locations (2)

32809

Orlando

33014

Miami

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY